1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,220 | 1,350 | 28.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BOAN BIOTECH (06955): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| Mo | BOAN BIOTECH (06955): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| SHANDONG BOAN BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 17.06. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR BA1302 IN THE U.S. | 1 | HKEx | ||
| 11.06. | BOAN BIOTECH (06955): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 11.06. | BOAN BIOTECH (06955): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 05.06. | BOAN BIOTECH (06955): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 05.06. | BOAN BIOTECH (06955): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2025, APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR, CHANGES ... | - | HKEx | ||
| 05.06. | BOAN BIOTECH (06955): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 04.06. | BOAN BIOTECH (06955): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 5 JUNE 2025 (APPLICABLE TO HOLDERS OF H SHARES) | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): (1) 2024 REPORT OF THE BOARD OF DIRECTORS (2) 2024 REPORT OF THE BOARD OF SUPERVISORS (3) 2024 ANNUAL REPORT (4) PROPOSED APPOINTMENT ... | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): ANNUAL REPORT 2024 | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 27.03. | BOAN BIOTECH (06955): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 | 1 | HKEx | ||
| 27.03. | BOAN BIOTECH (06955): PROPOSED APPOINTMENTS OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 26.03. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT BA1302 GRANTED ODD FOR SQNSCLC AND PANCREATIC CANCER BY U.S. FDA | - | HKEx | ||
| 14.03. | BOAN BIOTECH (06955): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 24.01. | BOAN BIOTECH (06955): FINANCE LEASE AGREEMENT | 3 | HKEx |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
SHANDONG BOAN BIOTECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANDONG BOAN BIOTECHNOLOGY CO LTD finden Sie auf Wallstreet Online.